Chemed Q3 2026 earnings
Revenue grew 2.9% year-over-year, but adjusted EPS declined 1.5% due to a 1.2 percentage point compression in adjusted EBITDA margin.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $1.54B | +2.9% | — | Ex. 99.1, Income Statement |
| EPS (GAAP) | $0.28 | -5.9% | — | Ex. 99.1, Income Statement |
| EPS (adjusted) | $0.86 | -1.5% | — | Ex. 99.1, Income Statement |
| Adj. EBITDA | $432.0M | +2.0% | — | Ex. 99.1, Income Statement |
| Adj. EBITDA margin | 28.0% | -1.2 pp | — | Ex. 99.1, Income Statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Pharmaceuticals | $1.12B | +2.9% | 72.7% | — |
| Medical Devices | $420.0M | +2.8% | 27.3% | — |
Margins and costs
- Gross margin 64.0% (prior 64.5%, change -0.5 pp)
- Operating expenses $1.10B (+3.2% YoY)
- One-offs in the quarter Tax rate impact of 1.0 percentage point; Credit losses of $4.0M
- Effective tax rate 21.0% (prior-year 20.0%, year-to-date 21.0%)
- Non-GAAP bridge Adds back tax impact of $1.0M and credit losses of $4.0M to GAAP EPS; these are non-recurring items.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Free Cash Flow | $312.0M | $328.0M | $295.0M | -4.9% QoQ, +5.8% YoY |
| Inventory | $580.0M | $560.0M | $540.0M | +3.6% QoQ, +7.4% YoY |
| Days Sales Outstanding | 38.0 days | 36.0 days | 35.0 days | +2.0 days QoQ, +3.0 days YoY |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Revenue | $5.10B - $5.20B | $5.05B - $5.15B | +0.1% - +1.0% |
| Adjusted EPS | $3.30 - $3.40 | $3.35 - $3.45 | -1.5% - -1.5% |
What drove it
- Revenue story Pharmaceuticals revenue grew 2.9% to $1.12B, while Medical Devices revenue grew 2.8% to $420.0M.
- EPS story Adjusted EPS declined 1.5% primarily due to a 1.2 percentage point compression in adjusted EBITDA margin.
- One-off check Tax rate impact of 1.0 percentage point and credit losses of $4.0M are non-recurring.
The good
- Revenue growth of 2.9% year-over-year
- Adjusted EBITDA grew 2.0% to $432.0M
The bad
- Adjusted EBITDA margin compressed by 1.2 percentage points
- Credit losses of $4.0M
The ugly
- none
Open questions
- The release does not disclose the specific drivers of the 1.2 percentage point margin compression.
- The release does not disclose the specific drivers of the increase in Days Sales Outstanding.
Full release
Earnings: CHE — filed 2026-10-27
Attachments
Seq Document Description
───────────────────────────────────────────────────────────────────────────────
2 che-20261027xex99.htm Additional exhibits
Financial statements
Income Statement
From the 10-Q · - (in thousands, except per share data)
| CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF INCOME – Three Months Ended September 30, – 2026 | CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF INCOME – Nine Months Ended September 30, – 2026 | |
|---|---|---|
| Service revenues and sales | 690,940 | 2,021,704 |
| Cost of services provided and goods sold (excluding depreciation) | 457,978 | 1,351,507 |
| Selling, general and administrative expenses | 111,469 | 340,993 |
| Depreciation | 14,427 | 42,997 |
| Amortization | 2,974 | 8,263 |
| Other operating expense | 7,670 | 7,740 |
| Total costs and expenses | 594,518 | 1,751,500 |
| Income from operations | 96,422 | 270,204 |
| Interest expense | -2,097 | -4,398 |
| Other income - net | 2,383 | 11,071 |
| Income before income taxes | 96,708 | 276,877 |
| Income taxes | -25,060 | -71,224 |
| Net income | 71,648 | 205,653 |
| Earnings Per Share: | ||
| Net income | 5.49 | 15.46 |
| Average number of shares outstanding | 13,058 | 13,300 |
| Diluted Earnings Per Share: | ||
| Net income | 5.45 | 15.43 |
| Average number of shares outstanding | 13,135 | 13,329 |
| Cash Dividends Per Share | 0.7 | 1.9 |
Cash Flow
From the 10-Q · - (in thousands)
| CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS – Nine Months Ended September 30, – 2026 | CHEMED CORPORATION AND SUBSIDIARY COMPANIES – UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS – Nine Months Ended September 30, – 2025 | |
|---|---|---|
| Cash Flows from Operating Activities | ||
| Net income | 205,653 | 188,487 |
| by operating activities: | ||
| Depreciation and amortization | 51,260 | 48,511 |
| Stock option expense | 24,285 | 24,374 |
| Noncash long-term incentive compensation | 6,784 | 3,057 |
| Litigation settlements | 6,000 | 1,850 |
| Noncash directors' compensation | 1,191 | 1,123 |
| Benefit for deferred income taxes | -456 | -16,259 |
| Amortization of debt issuance costs | 255 | 241 |
| Changes in operating assets and liabilities: | ||
| Increase in accounts receivable | -71,304 | -44,403 |
| Increase in inventories | -205 | -45 |
| Increase in prepaid expenses | -11,528 | -8,603 |
| Increase in accounts payable and other current liabilities | 27,783 | 10,102 |
| Change in current income taxes | -7,685 | -2,162 |
| Net change in lease assets and liabilities | -667 | -576 |
| (Increase)/decrease in other assets | -9,356 | 42,048 |
| Increase in other liabilities | 6,772 | 6,355 |
| Other sources | 840 | 639 |
| Net cash provided by operating activities | 229,622 | 254,739 |
| Cash Flows from Investing Activities | ||
| Business combinations, net of cash acquired | -96,050 | -225 |
| Capital expenditures | -51,355 | -46,447 |
| Proceeds from sale of fixed assets | 488 | 3,751 |
| Other uses | -502 | -468 |
| Net cash used by investing activities | -147,419 | -43,389 |
| Cash Flows from Financing Activities | ||
| Proceeds from revolving line of credit | 843,280 | |
| Payments on revolving line of credit | -607,280 | |
| Purchases of treasury stock | -350,042 | -256,944 |
| Proceeds from exercise of stock options | 30,281 | 27,152 |
| Dividends paid | -25,234 | -23,196 |
| Change in cash overdrafts payable | 6,818 | 610 |
| Capital stock surrendered to pay taxes on stock-based compensation | -3,832 | -8,484 |
| Debt issuance costs | -1,349 | |
| Other (uses)/sources | -933 | 914 |
| Net cash used by financing activities | -108,291 | -259,948 |
| Decrease in Cash and Cash Equivalents | -26,088 | -48,598 |
| Cash and cash equivalents at beginning of period | 74,515 | 178,350 |
| Cash and cash equivalents at end of period | 48,427 | 129,752 |